This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Global Registry for Long-Term Follow-up of Posoleucel

  • Research type

    Research Study

  • Full title

    Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)

  • IRAS ID

    1005578

  • Contact name

    Dawid Olejniczak

  • Contact email

    ALVRRegistryP-105-401_4690-0012@iconplc.com

  • Sponsor organisation

    AlloVir, Inc.

  • Eudract number

    2022-000763-45

  • ISRCTN Number

    ISRCTN31439492

  • Research summary

    Posoleucel (or ALVR105) is a research medicine that contains T-cells made from healthy human donors to defend patients against specific viruses. The purpose of this registry study is to follow up with children and adult patients who were enrolled in Posoleucel clinical trials, in order to obtain long-term safety, effectiveness, and healthcare utilization information after treatment with Posoleucel or placebo. Recording patient health information over time can help to supplement the original study results and improve the care of patients in the future.

  • REC name

    Yorkshire & The Humber - Sheffield Research Ethics Committee

  • REC reference

    22/YH/0139

  • Date of REC Opinion

    10 Aug 2022

  • REC opinion

    Further Information Favourable Opinion

We need your feedback!

We are still testing the new HRA website to ensure it meets your needs. Please complete our short feedback form.